Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

Biochemistry, Antithrombin III

In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Free Books & Documents
Book

Biochemistry, Antithrombin III

Eric Hsu et al.
Free Books & Documents

Excerpt

Antithrombin is a plasma glycoprotein consisting of 432 amino acid residues integral in the regulation of the coagulation process during bleeding. Antithrombin most notably binds to serine proteases factor II (thrombin), factor IXa, and factor Xa which inhibits the blood clotting process involved in the coagulation cascade pathway. As part of the normal physiological response to bleeding, platelets circulating the plasma become initially activated by multiple factors produced from endothelial cells to aggregate and form a plug. Circulating fibrinogen is then converted into fibrin by thrombin through a series of protease activations, which constitute the reactions of the coagulation cascade pathway. Fibrin acts to stabilize the initial platelet-created plug which determines the completion of the clot formation.

Antithrombin is among the number of regulatory mechanisms of the coagulation cascade which provides a counter mechanism to clot formation. It serves as up to 80% of the inhibitory component to thrombin formation, as well as factor IXa and factor Xa inhibition. Deficiency in antithrombin has clinical links to increased risks of thrombosis, thromboembolism, and associated complications associated with a hypercoagulable state. This activity aims to provide a generalized understanding of the biochemical properties of anti-thrombin, present an overview of its structure in correlation to its function regarding interactions with serine proteases and heparin.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Eric Hsu declares no relevant financial relationships with ineligible companies.

Disclosure: Leila Moosavi declares no relevant financial relationships with ineligible companies.

References

    1. O'Donnell JS, O'Sullivan JM, Preston RJS. Advances in understanding the molecular mechanisms that maintain normal haemostasis. Br J Haematol. 2019 Jul;186(1):24-36. - PubMed
    1. Bae J, Desai UR, Pervin A, Caldwell EE, Weiler JM, Linhardt RJ. Interaction of heparin with synthetic antithrombin III peptide analogues. Biochem J. 1994 Jul 01;301 ( Pt 1)(Pt 1):121-9. - PMC - PubMed
    1. Bravo-Pérez C, Vicente V, Corral J. Management of antithrombin deficiency: an update for clinicians. Expert Rev Hematol. 2019 Jun;12(6):397-405. - PubMed
    1. Ersdal-Badju E, Lu A, Zuo Y, Picard V, Bock SC. Identification of the antithrombin III heparin binding site. J Biol Chem. 1997 Aug 01;272(31):19393-400. - PubMed
    1. Karlaftis V, Sritharan G, Attard C, Corral J, Monagle P, Ignjatovic V. Beta (β)-antithrombin activity in children and adults: implications for heparin therapy in infants and children. J Thromb Haemost. 2014 Jul;12(7):1141-4. - PubMed

Publication types

LinkOut - more resources